Clinical Trial Update: Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts [Phase 3]

View source ↗

Summary

Phase 3 randomized study of ON 01910.Na in refractory myelodysplastic syndromes with excess blasts completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excess Blasts in Mds
• Myelodysplastic Syndromes

Drugs mentioned

• ON-01910.Na (ON-01910 sodium)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndromes, MDS | Phase 3 | Status: COMPLETED